Effect of aripiprazole on self-reported anhedonia in bipolar depressed patients

Psychiatry Research

Volumn 165, Issue 1-2, 2009, Pages 193-196

  Mazza, Marianna ^a   Squillacioti, Maria Rosaria ^a   Pecora, Riccardo Daniele ^b   Janiri, Luigi ^a   Bria, Pietro ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b ASL Frosinone   (Italy)

Author keywords

Anhedonia; Aripiprazole; Bipolar disorder; Depression; MADRS; SHAPS

Indexed keywords

ARIPIPRAZOLE;

ADULT; AKATHISIA; ANHEDONIA; ARTICLE; BIPOLAR DEPRESSION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; RATING SCALE; SELF REPORT;

ADULT; AFFECT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PERSONALITY INVENTORY; PIPERAZINES; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; QUINOLONES;

EID: 57749191725     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2008.05.003     Document Type: Article

References (14)

1. Aihara K., Shimada J., Miwa T., Tottori K., Burris K.D., Yocca F.D., Horie M., and Kikuchi T. The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release. Brain Research 1003 1-2 (2004) 9-17
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. (1994), APA, Washington, DC
3. Etain B., Roy I., Henry C., Rousseva A., Schurhoff F., Leboyer M., and Bellivier F. No evidence for physical anhedonia as a candidate symptom or an endophenotype in bipolar affective disorder. Bipolar Disorders 9 7 (2007) 706-712
4. Keck P.E., Calabrese J.R., McIntyre R.S., McQuade R.D., Carson W.H., Eudicone J.M., Carlson B.X., Marcus R.N., Sanchez R., and for the Aripiprazole Study Group. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. Journal of Clinical Psychiatry 68 (2007) 1480-1491
5. Kemp D.E., Gilmer W.S., Fleck L., Straus J.L., Dago P.L., and Karaffa M. Aripiprazole augmentation in treatment-resistant bipolar depression: early response and development of akathisia. Progress in Neuro-Psychopharmacology & Biological Psychiatry 31 (2007) 574-577
6. 2 receptor partial agonism?. American Journal of Psychiatry 164 9 (2007) 1310-1312
7. McElroy S.L., Suppes T., Frye M.A., Altshuler L.L., Stanford K., Martens B., Leverich G.S., Post R.M., and Keck Jr. P.E. Open-label aripiprazole in the treatment of acute bipolar depression: a prospective pilot trial. Journal of Affective Disorders 101 1-3 (2007) 275-281
8. McIntyre R.S., Soczynska J.K., Woldeyohannes H.O., Miranda A., and Konarski J.Z. Aripiprazole: pharmacology and evidence in bipolar disorder. Expert Opinion on Pharmacotherapy 8 7 (2007) 1001-1009
9. Montgomery S.A., and Åsberg M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry 134 (1979) 382-389
10. Pae C.U., Serretti A., Patkar A.A., and Masand P.S. Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence. CNS Drugs 22 5 (2008) 367-388
11. Serretti A., and Olgiati P. Dimensions of major psychoses: a confirmatory factor analysis of six competing models. Psychiatry Research 127 1-2 (2004) 101-109
12. Snaith R.P., Hamilton M., Morley S., Humayan A., Hargreaves D., and Trigwell P. A scale for the assessment of hedonic tone: the Snaith-Hamilton Pleasure Scale. British Journal of Psychiatry 167 1 (1995) 99-103
13. Sokolski K.N. Adjunctive aripiprazole in bipolar I depression. Annals of Pharmacotherapy 41 1 (2007) 35-40
14. Young R.C., Biggs J.T., Ziegler V.E., and Meyer D.A. A rating scale for mania: reliability, validity and sensitivity. British Journal of Psychiatry 133 (1978) 429-435